VGXI Blog & News

Welcome to the VGXI blog where we examine scientific trends, innovation, technological advancements in plasmid DNA manufacturing, and uncover how next-generation therapeutics are shaping the future of medicine and improving patients’ lives.

VGXI Completes Successful FDA Inspection Enabling Client BLA Approval Milestone, Advancing Its Leadership in Plasmid DNA Manufacturing

CONROE, Texas — VGXI, Inc., a leading contract development and manufacturing organization (CDMO) specializing in plasmid DNA biopharmaceuticals, including for use in gene therapies, DNA vaccines, and RNA medicines, proudly announces it has recently completed a successful inspection by[…]

  Read More

VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies

Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene[…]

  Read More

VGXI to Attend Alliance for Regenerative Medicine Annual Meeting on the Mesa

Conroe, Texas – VGXI, Inc., a leading provider of plasmid DNA manufacturing and development[…]

  Read More

VGXI accepted as a Member of the Biopharmaceutical Manufacturing Preparedness (BioMap) Consortium

VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid[…]

  Read More

VGXI, accepted as a Member of the US Government’s Rapid Response Partnership Vehicle (RRPV)

VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid[…]

  Read More

Future Proof Your Advanced Therapies Supply Chain with VGXI’s US-Based Plasmid CDMO Expertise

In the current landscape of biopharmaceutical drug development, finding a reliable and[…]

  Read More

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid[…]

  Read More

VGXI’s Expanded Manufacturing Capacity Addresses Plasmid DNA Supply Chain Challenges

Plasmid DNA (pDNA) is an essential part of the supply chain for advanced therapies and[…]

  Read More

Five Qualities to Look for in a CDMO

As the biopharmaceutical industry increasingly turns to outsourcing, the key to success lies in[…]

  Read More

Stephanie Burke Named as VGXI’s New Chief Accounting Officer

Leading plasmid DNA CDMO VGXI, Inc. announces the appointment of Stephanie Burke as its new[…]

  Read More